Bipolar Disorder an Information Guide Revised Edition
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Paranoid – Suspicious; Argumentative; Paranoid; Continually on The
Disorder Gathering 34, 36, 49 Answer Keys A N S W E R K E Y, Disorder Gathering 34 1. Avital Agoraphobia – 2. Ewelina Alcoholism – 3. Martyna Anorexia – 4. Clarissa Bipolar Personality Disorder –. 5. Lysette Bulimia – 6. Kev, Annabelle Co-Dependant Relationship – 7. Archer Cognitive Distortions / all-of-nothing thinking (Splitting) – 8. Josephine Cognitive Distortions / Mental Filter – 9. Mendel Cognitive Distortions / Disqualifying the Positive – 10. Melvira Cognitive Disorder / Labeling and Mislabeling – 11. Liat Cognitive Disorder / Personalization – 12. Noa Cognitive Disorder / Narcissistic Rage – 13. Regev Delusional Disorder – 14. Connor Dependant Relationship – 15. Moira Dissociative Amnesia / Psychogenic Amnesia – (*Jason Bourne character) 16. Eylam Dissociative Fugue / Psychogenic Fugue – 17. Amit Dissociative Identity Disorder / Multiple Personality Disorder – 18. Liam Echolalia – 19. Dax Factitous Disorder – 20. Lorna Neurotic Fear of the Future – 21. Ciaran Ganser Syndrome – 22. Jean-Pierre Korsakoff’s Syndrome – 23. Ivor Neurotic Paranoia – 24. Tucker Persecutory Delusions / Querulant Delusions – 25. Lewis Post-Traumatic Stress Disorder – 26. Abdul Proprioception – 27. Alisa Repressed Memories – 28. Kirk Schizophrenia – 29. Trevor Self-Victimization – 30. Jerome Shame-based Personality – 31. Aimee Stockholm Syndrome – 32. Delphine Taijin kyofusho (Japanese culture-specific syndrome) – 33. Lyndon Tourette’s Syndrome – 34. Adar Social phobias – A N S W E R K E Y, Disorder Gathering 36 Adjustment Disorder – BERKELEY Apotemnophilia -
First Episode Psychosis an Information Guide Revised Edition
First episode psychosis An information guide revised edition Sarah Bromley, OT Reg (Ont) Monica Choi, MD, FRCPC Sabiha Faruqui, MSc (OT) i First episode psychosis An information guide Sarah Bromley, OT Reg (Ont) Monica Choi, MD, FRCPC Sabiha Faruqui, MSc (OT) A Pan American Health Organization / World Health Organization Collaborating Centre ii Library and Archives Canada Cataloguing in Publication Bromley, Sarah, 1969-, author First episode psychosis : an information guide : a guide for people with psychosis and their families / Sarah Bromley, OT Reg (Ont), Monica Choi, MD, Sabiha Faruqui, MSc (OT). -- Revised edition. Revised edition of: First episode psychosis / Donna Czuchta, Kathryn Ryan. 1999. Includes bibliographical references. Issued in print and electronic formats. ISBN 978-1-77052-595-5 (PRINT).--ISBN 978-1-77052-596-2 (PDF).-- ISBN 978-1-77052-597-9 (HTML).--ISBN 978-1-77052-598-6 (ePUB).-- ISBN 978-1-77114-224-3 (Kindle) 1. Psychoses--Popular works. I. Choi, Monica Arrina, 1978-, author II. Faruqui, Sabiha, 1983-, author III. Centre for Addiction and Mental Health, issuing body IV. Title. RC512.B76 2015 616.89 C2015-901241-4 C2015-901242-2 Printed in Canada Copyright © 1999, 2007, 2015 Centre for Addiction and Mental Health No part of this work may be reproduced or transmitted in any form or by any means electronic or mechanical, including photocopying and recording, or by any information storage and retrieval system without written permission from the publisher—except for a brief quotation (not to exceed 200 words) in a review or professional work. This publication may be available in other formats. For information about alterna- tive formats or other CAMH publications, or to place an order, please contact Sales and Distribution: Toll-free: 1 800 661-1111 Toronto: 416 595-6059 E-mail: [email protected] Online store: http://store.camh.ca Website: www.camh.ca Disponible en français sous le titre : Le premier épisode psychotique : Guide pour les personnes atteintes de psychose et leur famille This guide was produced by CAMH Publications. -
Two Cases of Intractable Auditory Hallucination Successfully Treated with Sound Therapy
ORIGINAL ARTICLE International Tinnitus Journal. 2010;16(1):29-31. Two cases of intractable auditory hallucination successfully treated with sound therapy Yutaka Kaneko, M.D. 1 Yasuhiko Oda, M.D. 2 Fumiyuki Goto, M.D. 3 Abstract We report two cases of patients with schizoaffective disorder with treatment-refractory auditory verbal hallucinations (AVHs) who were successfully treated with sound therapy, which is effective to treat tinnitus. AVHs in both patients were alleviated within about one month, and no recurrence was reported for 31 and 17 months after the sound the- rapy together with medication. Further studies may confirm the therapeutic value of sound therapy in patients with intractable AVHs. Keywords: auditory hallucinations, sound therapy. 1 Kaneko Otorhinolaryngology Clinic, Sendai, Miyagi, 2 Kunimidai Hospital (Psychiatry), Sendai, Miyagi, and 3 Department of Otorhinolaryngology, Hino Municipal Hospital, Tokyo, Japan Corresponding Author: Yutaka Kaneko, M.D. Kaneko Otorhinolaryngology Clinic 2-9-14 Kunimi,Aoba-ku,Sendai 981-0943,Japan Tel & Fax: +81-22-233-7722 E-mail: [email protected] International Tinnitus Journal, Vol. 16, No 1 (2010) www.tinnitusjournal.com 29 INTRODUCTION levomepromazine and olanzapine, together with fluvo- xamine maleate and sodium valproate during her hos- Auditory hallucinations (AHs) are generally defined pitalization for 3 years. She then received a psychiatric as false perceptions manifesting as “voices commenting” referral to our ear clinic for audiological evaluation and or “voices conversing” in patients with schizophrenia and treatment in August 2006. Her hearing level, calculated schizoaffective disorder. Auditory verbal hallucinations as the average across the frequencies 250, 500, 1000, (AVHs) are one of the major symptoms for the diagnosis and 2000 Hz, was 13.8 dB in the right ear and 18.8 dB of these disorders as well as the evaluation of psychotic in the left ear. -
Is Your Depressed Patient Bipolar?
J Am Board Fam Pract: first published as 10.3122/jabfm.18.4.271 on 29 June 2005. Downloaded from EVIDENCE-BASED CLINICAL MEDICINE Is Your Depressed Patient Bipolar? Neil S. Kaye, MD, DFAPA Accurate diagnosis of mood disorders is critical for treatment to be effective. Distinguishing between major depression and bipolar disorders, especially the depressed phase of a bipolar disorder, is essen- tial, because they differ substantially in their genetics, clinical course, outcomes, prognosis, and treat- ment. In current practice, bipolar disorders, especially bipolar II disorder, are underdiagnosed. Misdi- agnosing bipolar disorders deprives patients of timely and potentially lifesaving treatment, particularly considering the development of newer and possibly more effective medications for both depressive fea- tures and the maintenance treatment (prevention of recurrence/relapse). This article focuses specifi- cally on how to recognize the identifying features suggestive of a bipolar disorder in patients who present with depressive symptoms or who have previously been diagnosed with major depression or dysthymia. This task is not especially time-consuming, and the interested primary care or family physi- cian can easily perform this assessment. Tools to assist the physician in daily practice with the evalua- tion and recognition of bipolar disorders and bipolar depression are presented and discussed. (J Am Board Fam Pract 2005;18:271–81.) Studies have demonstrated that a large proportion orders than in major depression, and the psychiat- of patients in primary care settings have both med- ric treatments of the 2 disorders are distinctly dif- ical and psychiatric diagnoses and require dual ferent.3–5 Whereas antidepressants are the treatment.1 It is thus the responsibility of the pri- treatment of choice for major depression, current mary care physician, in many instances, to correctly guidelines recommend that antidepressants not be diagnose mental illnesses and to treat or make ap- used in the absence of mood stabilizers in patients propriate referrals. -
Conflict, Arousal, and Logical Gut Feelings
CONFLICT, AROUSAL, AND LOGICAL GUT FEELINGS Wim De Neys1, 2, 3 1 ‐ CNRS, Unité 3521 LaPsyDÉ, France 2 ‐ Université Paris Descartes, Sorbonne Paris Cité, Unité 3521 LaPsyDÉ, France 3 ‐ Université de Caen Basse‐Normandie, Unité 3521 LaPsyDÉ, France Mailing address: Wim De Neys LaPsyDÉ (Unité CNRS 3521, Université Paris Descartes) Sorbonne - Labo A. Binet 46, rue Saint Jacques 75005 Paris France [email protected] ABSTRACT Although human reasoning is often biased by intuitive heuristics, recent studies on conflict detection during thinking suggest that adult reasoners detect the biased nature of their judgments. Despite their illogical response, adults seem to demonstrate a remarkable sensitivity to possible conflict between their heuristic judgment and logical or probabilistic norms. In this chapter I review the core findings and try to clarify why it makes sense to conceive this logical sensitivity as an intuitive gut feeling. CONFLICT, AROUSAL, AND LOGICAL GUT FEELINGS Imagine you’re on a game show. The host shows you two metal boxes that are both filled with $100 and $1 dollar bills. You get to draw one note out of one of the boxes. Whatever note you draw is yours to keep. The host tells you that box A contains a total of 10 bills, one of which is a $100 note. He also informs you that Box B contains 1000 bills and 99 of these are $100 notes. So box A has got one $100 bill in it while there are 99 of them hiding in box B. Which one of the boxes should you draw from to maximize your chances of winning $100? When presented with this problem a lot of people seem to have a strong intuitive preference for Box B. -
DCF Pamphlet 155-2: Appendix 3
DCF Pamphlet 155-2: Appendix 3 Appendix 3: The table below shows the ICD9 codes that are acceptable in the Substance Abuse and Mental Health Information System (SAMHIS). This replaces all previous versions of allowable ICD9 codes used in the Substance Abuse and Mental Health Information System. The following are the codes and their meaning. STATUS: 0 = Inactive, code is not usable, 1 = Active, this will show in SAMHIS. PROGRAM CODE: N = Not Active, M = Mental Health Code, S = Substance Abuse Code B = Behavioral Health (can be used for either a mental health or substance abuse diagnosis) NOTE: Codes with ‘N’ (Not Active) in the Program Code are for historical purposes only. ICD9 PROGRAM Code STATUS DESCRIPTION CODE 095.7 0 SYPHILIS OF TENDON/BURSA N 196.8 0 MAL NEO LYMPH NODE-MULT N 259.9 0 ENDOCRINE DISORDER NOS N 269.0 0 DEFICIENCY OF VITAMIN K N 289.9 0 BLOOD DISEASE NOS N 290 0 Senile and presenile organic psychotic conditions N 290.0 0 SENILE DEMENTIA UNCOMP N 290.1 0 Presenile dementia N 290.10 0 PRESENILE DEMENTIA N 290.11 0 PRESENILE DELIRIUM N 290.12 0 PRESENILE DELUSION M 290.13 0 PRESENILE DEPRESSION M 290.2 0 Senile dementia with delusional or depressive feat M 290.20 0 SENILE DELUSION M 290.21 0 SENILE DEPRESSIVE M 290.3 0 SENILE DELIRIUM N 290.4 0 Arteriosclerotic dementia N 290.40 0 ARTERIOSCLER DEMENT NOS N 290.41 0 ARTERIOSCLER DELIRIUM N 290.42 0 ARTERIOSCLER DELUSION M 290.43 0 ARTERIOSCLER DEPRESSIVE M 290.8 0 SENILE PSYCHOSIS NEC N 290.9 0 SENILE PSYCHOT COND NOS N 291 1 Alcohol psychoses S 291.0 1 DELIRIUM TREMENS -
Types of Bipolar Disorder Toms Are Evident
MOOD DISORDERS ASSOCIATION OF BRITISH COLUmbIA T Y P E S O F b i p o l a r d i s o r d e r Bipolar disorder is a class of mood disorders that is marked by dramatic changes in mood, energy and behaviour. The key characteristic is that people with bipolar disorder alternate be- tween episodes of mania (extreme elevated mood) and depression (extreme sadness). These episodes can last from hours to months. The mood distur- bances are severe enough to cause marked impairment in the person’s func- tioning. The experience of mania is not pleasant and can be very frightening to The Diagnotistic Statisti- the person. It can lead to impulsive behaviour that has serious consequences cal Manual (DSM- IV-TR) is a for the person and their family. A depressive episode makes it difficult or -im manual used by doctors to possible for a person to function in their daily life. determine the specific type of bipolar disorder. People with bipolar disorder vary in how often they experience an episode of either mania or depression. Mood changes with bipolar disorder typically occur gradually. For some individuals there may be periods of wellness between the different mood episodes. Some people may also experience multiple episodes within a 12 month period, a week, or even a single day (referred to as “rapid cycling”). The severity of the mood can also range from mild to severe. Establishing the particular type of bipolar disorder can greatly aid in determin- ing the best type of treatment to manage the symptoms. -
Pharmacogenomic Characterization in Bipolar Spectrum Disorders
pharmaceutics Review Pharmacogenomic Characterization in Bipolar Spectrum Disorders Stefano Fortinguerra 1,2 , Vincenzo Sorrenti 1,2,3 , Pietro Giusti 2, Morena Zusso 2 and Alessandro Buriani 1,2,* 1 Maria Paola Belloni Center for Personalized Medicine, Data Medica Group (Synlab Limited), 35131 Padova, Italy; [email protected] (S.F.); [email protected] (V.S.) 2 Department of Pharmaceutical & Pharmacological Sciences, University of Padova, 35131 Padova, Italy; [email protected] (P.G.); [email protected] (M.Z.) 3 Bendessere™ Study Center, Solgar Italia Multinutrient S.p.A., 35131 Padova, Italy * Correspondence: [email protected] Received: 25 November 2019; Accepted: 19 December 2019; Published: 21 December 2019 Abstract: The holistic approach of personalized medicine, merging clinical and molecular characteristics to tailor the diagnostic and therapeutic path to each individual, is steadily spreading in clinical practice. Psychiatric disorders represent one of the most difficult diagnostic challenges, given their frequent mixed nature and intrinsic variability, as in bipolar disorders and depression. Patients misdiagnosed as depressed are often initially prescribed serotonergic antidepressants, a treatment that can exacerbate a previously unrecognized bipolar condition. Thanks to the use of the patient’s genomic profile, it is possible to recognize such risk and at the same time characterize specific genetic assets specifically associated with bipolar spectrum disorder, as well as with the individual response to the various therapeutic options. This provides the basis for molecular diagnosis and the definition of pharmacogenomic profiles, thus guiding therapeutic choices and allowing a safer and more effective use of psychotropic drugs. Here, we report the pharmacogenomics state of the art in bipolar disorders and suggest an algorithm for therapeutic regimen choice. -
Panic Disorder Issue Brief
Panic Disorder OCTOBER | 2018 Introduction Briefings such as this one are prepared in response to petitions to add new conditions to the list of qualifying conditions for the Minnesota medical cannabis program. The intention of these briefings is to present to the Commissioner of Health, to members of the Medical Cannabis Review Panel, and to interested members of the public scientific studies of cannabis products as therapy for the petitioned condition. Brief information on the condition and its current treatment is provided to help give context to the studies. The primary focus is on clinical trials and observational studies, but for many conditions there are few of these. A selection of articles on pre-clinical studies (typically laboratory and animal model studies) will be included, especially if there are few clinical trials or observational studies. Though interpretation of surveys is usually difficult because it is unclear whether responders represent the population of interest and because of unknown validity of responses, when published in peer-reviewed journals surveys will be included for completeness. When found, published recommendations or opinions of national organizations medical organizations will be included. Searches for published clinical trials and observational studies are performed using the National Library of Medicine’s MEDLINE database using key words appropriate for the petitioned condition. Articles that appeared to be results of clinical trials, observational studies, or review articles of such studies, were accessed for examination. References in the articles were studied to identify additional articles that were not found on the initial search. This continued in an iterative fashion until no additional relevant articles were found. -
The Implications of Hypersomnia in the Context of Major Depression: Results from a Large, International, Observational Study
ARTICLE IN PRESS JID: NEUPSY [m6+; March 2, 2019;10:45 ] European Neuropsychopharmacology (2019) 000, 1–11 www.elsevier.com/locate/euroneuro The implications of hypersomnia in the context of major depression: Results from a large, international, observational study a a, b c a A. Murru , G. Guiso , M. Barbuti , G. Anmella , a, d ,e a ,f , g g h N. Verdolini , L. Samalin , J.M. Azorin , J. Jules Angst , i j k a, l C.L. Bowden , S. Mosolov , A.H. Young , D. Popovic , m c a, ∗ a M. Valdes , G. Perugi , E. Vieta , I. Pacchiarotti , For the BRIDGE-II-Mix Study Group a Barcelona Bipolar and Depressive Disorders Unit, Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain b Clinica Psichiatrica, Dipartimento di Igiene e Sanità, Università di Cagliari, Italy c Division of Psychiatry, Clinical Psychology and Rehabilitation, Department of Medicine, University of Perugia, Santa Maria della Misericordia Hospital, Edificio Ellisse, 8 Piano, Sant’Andrea delle Fratte, 06132, Perugia, Italy d FIDMAG Germanes Hospitalàries Research Foundation, Sant Boi de Llobregat, Barcelona, Catalonia, Spain e Division of Psychiatry, Clinical Psychology and Rehabilitation, Department of Medicine, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy f CHU Clermont-Ferrand, Department of Psychiatry, University of Auvergne, Clermont-Ferrand, France g Fondation FondaMental, Hôpital Albert Chenevier, Pôle de Psychiatrie, Créteil, France h Department of Psychiatry, Psychotherapy and Psychosomatics, -
Specificity of Psychosis, Mania and Major Depression in A
Molecular Psychiatry (2014) 19, 209–213 & 2014 Macmillan Publishers Limited All rights reserved 1359-4184/14 www.nature.com/mp ORIGINAL ARTICLE Specificity of psychosis, mania and major depression in a contemporary family study CL Vandeleur1, KR Merikangas2, M-PF Strippoli1, E Castelao1 and M Preisig1 There has been increasing attention to the subgroups of mood disorders and their boundaries with other mental disorders, particularly psychoses. The goals of the present paper were (1) to assess the familial aggregation and co-aggregation patterns of the full spectrum of mood disorders (that is, bipolar, schizoaffective (SAF), major depression) based on contemporary diagnostic criteria; and (2) to evaluate the familial specificity of the major subgroups of mood disorders, including psychotic, manic and major depressive episodes (MDEs). The sample included 293 patients with a lifetime diagnosis of SAF disorder, bipolar disorder and major depressive disorder (MDD), 110 orthopedic controls, and 1734 adult first-degree relatives. The diagnostic assignment was based on all available information, including direct diagnostic interviews, family history reports and medical records. Our findings revealed specificity of the familial aggregation of psychosis (odds ratio (OR) ¼ 2.9, confidence interval (CI): 1.1–7.7), mania (OR ¼ 6.4, CI: 2.2–18.7) and MDEs (OR ¼ 2.0, CI: 1.5–2.7) but not hypomania (OR ¼ 1.3, CI: 0.5–3.6). There was no evidence for cross-transmission of mania and MDEs (OR ¼ .7, CI:.5–1.1), psychosis and mania (OR ¼ 1.0, CI:.4–2.7) or psychosis and MDEs (OR ¼ 1.0, CI:.7–1.4). -
Guidance on the Use of Mood Stabilizers for the Treatment of Bipolar Affective Disorder Version 2
Guidance on the use of mood stabilizers for the treatment of bipolar affective disorder Version 2 RATIFYING COMMITTEE DRUGS AND THERAPEUTICS GROUP DATE RATIFIED July 2015 REPLACES Version 1 dated July 2013 NEXT REVIEW DATE July 2017 POLICY AUTHORS Jules Haste, Lead Pharmacist, Brighton and Hove Members of the Pharmacy Team (contributors are listed overleaf) If you require this document in an alternative format, i.e. easy read, large text, audio or Braille please contact the pharmacy team on 01243 623349 Page 1 of 49 Contributors Jed Hewitt, Chief Pharmacist - Governance & Professional Practice James Atkinson, Pharmacist Team Leader Mental Health and Community Services Miguel Gomez, Lead Pharmacist, Worthing. Hilary Garforth, Lead Pharmacist, Chichester. Pauline Daw, Lead Pharmacist (CRHTs & AOT), East Sussex. Iftekhar Khan, Lead Pharmacist (S&F Service), East Sussex. Graham Brown, Lead Pharmacist CAMHS & EIS. Gus Fernandez, Specialist Pharmacist MI and MH Lisa Stanton, Specialist Pharmacist Early Intervention Services & Learning Disabilities. Nana Tomova, Specialist Pharmacist, Crawley. Page 2 of 49 Section Title Page Number Introduction and Key Points 4 1. General principles in the treatment of acute mania 6 2. General principles in the treatment of bipolar depression 8 3. General principles in long term treatment 10 4. Rapid cycling 13 5. Physical health 13 6. Treatment in special situations 6.1 Pregnancy 15 6.2 Breast-feeding 17 6.3 Older adults 19 6.4 Children and adolescents 22 6.5 Learning disabilities 29 6.6 Cardiac dysfunction 30 6.7 Renal dysfunction 34 6.8 Hepatic dysfunction 37 6.9 Epilepsy 41 7. The risk of switching to mania with antidepressants 43 8.